Funding for this research was provided by:
National Cancer Institute (T32 CA090223, R35 CA198183)
D. Warren Brown Family Foundation
Ohio State University Pelotonia Foundation
Four Winds Foundation
Received: 29 August 2019
Accepted: 7 November 2019
First Online: 28 January 2020
Ethics approval and consent to participate
: AML patient samples were obtained from The Ohio State University Comprehensive Cancer Center Leukemia Tissue Bank under an Institutional Review Board-approved protocol. All in vivo experiments were conducted after approval of The Ohio State University Institutional Animal Care and Use Committee.
: Not applicable
: S.E. and B.S. are current employees of ArQule, Inc. K.S. has previously consulted for Novartis and Rigel Pharmaceuticals and currently receives grant funding from Novartis. J.C.B. have or currently is consulting with Acerta, AstraZeneca, Pharmacyclics, and Jazz Pharmaceuticals. The other authors declare that they have no competing interests.